UPDATE 2-FDA panel votes against Novartis drug for acute heart failure Reuters Novartis filed for approval of the drug, serelaxin, based on a single study that showed that when given alongside standard treatment it alleviated shortness of breath by slowing the rate of worsening heart failure following hospitalization. Panelists ... FDA panel rejects Novartis' heart failure hope serelaxin FDA panel votes against Novartis drug for acute heart failure FDA Panel Rejects Novartis Drug for Heart Failure |
